Koka V N, Julieron M, Bourhis J, Janot F, Le Ridant A M, Marandas P, Luboinski B, Schwaab G
Department of Head and Neck Surgery, Institut Gustave Roussy, Villejuif, France.
J Laryngol Otol. 1998 Jul;112(7):628-33. doi: 10.1017/s0022215100141295.
Forty patients were treated or followed up for aesthesioneuroblastoma between 1980 and 1995 at Institut Gustave Roussy, France. There were three T1, seven T2, 15 T3 and 15 T4 lesions. The cervical metastatic rate at presentation was 18 per cent. Distant metastases were detected by bone marrow biopsy and bone scan in three patients at presentation. Treatment modalities included surgery alone in eight patients, radiotherapy alone in three patients, combined modality surgery plus radiotherapy in 11 patients, chemotherapy alone in two patients, chemotherapy plus radiotherapy in 10 patients, and multimodality therapy chemotherapy plus surgery plus radiotherapy in six patients. The five-year survival rate was 51 per cent. Multimodality treatment offered better survival (63 per cent at five years) and disease-free interval (54 months). Overall local, regional, and distant failure rates were 58 per cent, 15 per cent and 40 per cent respectively. Distant metastases commonly occurred in bone (82 per cent). Cervical metastasis was an unfavourable prognostic indicator (0 per cent survival at two years). In conclusion, aesthesioneuroblastoma is sensitive to chemotherapy and radiotherapy. Multimodality therapy should be used initially.
1980年至1995年间，法国古斯塔夫·鲁西研究所对40例嗅神经母细胞瘤患者进行了治疗或随访。其中有3例T1期、7例T2期、15例T3期和15例T4期病变。初诊时颈部转移率为18%。3例患者初诊时通过骨髓活检和骨扫描检测到远处转移。治疗方式包括8例单纯手术、3例单纯放疗、11例手术加放疗联合治疗、2例单纯化疗、10例化疗加放疗以及6例化疗加手术加放疗的多模式治疗。五年生存率为51%。多模式治疗的生存率更高（五年生存率为63%），无病生存期更长（54个月）。总体局部、区域和远处失败率分别为58%、15%和40%。远处转移常见于骨骼（82%）。颈部转移是一个不良预后指标（两年生存率为0%）。总之，嗅神经母细胞瘤对化疗和放疗敏感。应首选多模式治疗。
